Evidence map›Paper›PMID 42043735›Full record

ArticleEndocrine2026

Assessing Patient Characteristics in Neuroendocrine Tumor Research: A Comparison of the NET-PRO Study to SEER Population-Based Data.

Michael A O'Rorke, Bradley D McDowell, Tao Xu, Rhonda R DeCook, Brian M Gryzlak, Nicholas J Rudzianski, Kimberly C Serrano, Abigayle M Wehrheim, Udhayvir S Grewal, Chandrikha Chandrasekharan and 22 more

Registry-linked trialAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05064150 (A Cohort Study of Symptom Burden and Therapeutic Selection in Neuroendocrine Tumors), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05064150 active not recruitingnot on this map

A Cohort Study of Symptom Burden and Therapeutic Selection in Neuroendocrine Tumors (NETs)

TypeobservationalSponsorUniversity of IowaRan2022 to 2026Enrolled2,539ConditionsNeuroendocrine Tumors, Gastroenteropancreatic Neuroendocrine Tumor, Lung Neuroendocrine Neoplasm, Neuroendocrine Carcinoma
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

Michael A O'RorkeCollege of Public Health, Department of Epidemiology, University of Iowa, 145 N Riverside Drive, Iowa City, IA, 52242, USA. michael-ororke@uiowa.edu.ORCID 0000-0002-2425-3323
Bradley D McDowellCollege of Public Health, Department of Epidemiology, University of Iowa, 145 N Riverside Drive, Iowa City, IA, 52242, USA.
Tao XuCollege of Public Health, Department of Epidemiology, University of Iowa, 145 N Riverside Drive, Iowa City, IA, 52242, USA.
Rhonda R DeCookCollege of Public Health, Department of Epidemiology, University of Iowa, 145 N Riverside Drive, Iowa City, IA, 52242, USA.
Brian M GryzlakCollege of Public Health, Department of Epidemiology, University of Iowa, 145 N Riverside Drive, Iowa City, IA, 52242, USA.
Nicholas J RudzianskiCollege of Public Health, Department of Epidemiology, University of Iowa, 145 N Riverside Drive, Iowa City, IA, 52242, USA.
Kimberly C SerranoCollege of Public Health, Department of Epidemiology, University of Iowa, 145 N Riverside Drive, Iowa City, IA, 52242, USA.
Abigayle M WehrheimCollege of Public Health, Department of Epidemiology, University of Iowa, 145 N Riverside Drive, Iowa City, IA, 52242, USA.
Udhayvir S GrewalDepartment of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, IA, USA.
Chandrikha ChandrasekharanDepartment of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, IA, USA.
Joseph S DillonDepartment of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, IA, USA.
Thorvardur R HalfdanarsonMayo Clinic, Rochester, MN, USA.
Michael J SchnellMayo Clinic, Rochester, MN, USA.
Carrie L WitterMayo Clinic, Rochester, MN, USA.
T Clark GamblinMedical College of Wisconsin, Milwaukee, WI, USA.
Syed KazmiDepartment of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA.
Lindsay G CowellDepartment of Health Data Science and Biostatistics, O'Donnell School of Public Health, UT Southwestern Medical Center, Dallas, TX, USA.
Tobias ElseDepartment of Internal Medicine, Division of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, MI, USA.
Heloisa P SoaresHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Vineeth SukrithanDivision of Medical Oncology, Department of Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Sravani ChandakaUniversity of Kansas Medical Center, Kansas City, KS, USA.
Hanna K SanoffDivision of Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Fiona C HeAllina Health Cancer Institute, Minneapolis, MN, USA.
David A GellerUniversity of Pittsburgh, Pittsburgh, PA, USA.
Robert A RamirezDepartment of Internal Medicine, Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN, USA.
Mei LiuDepartment of Health Outcomes and Biomedical Informatics, College of Medicine, University of Florida, Gainesville, FL, USA.
William LancasterDepartment of Surgery, Medical University of South Carolina, Charleston, SC, USA.
Josh A MailmanNorCal CarciNET Community, Oakland, CA, USA.
Heather MoranThe Healing NET Foundation, Los Angeles, CA, USA.
Maryann WahmannNeuroendocrine Cancer Awareness Network, Fort Mill, SC, USA.
Elyse GellermanNeuroendocrine Tumor Research Foundation, Boston, MA, USA.
Elizabeth A ChrischillesCollege of Public Health, Department of Epidemiology, University of Iowa, 145 N Riverside Drive, Iowa City, IA, 52242, USA.

Funding

Project 3: GLP1R and GIPR Agonists in GEP NETs ProjectP50CA302572 · NCI · UNIVERSITY OF IOWA · PI JAMES R HOWE · 2025 to 2026
$6.5M
NCI NIH HHS P50 CA302572Patient-Centered Outcomes Research Institute RD-2020C2-20329
6 · The paper itself

Abstract

purposeWe compared demographic and clinical characteristics of patients with gastroenteropancreatic (GEP) and lung neuroendocrine tumors (NETs) enrolled in the NET-PRO study to those in the U.S. Surveillance Epidemiology and End Results (SEER) program to evaluate the comparability of NET-PRO as a resource for real-world evidence generation and patient reported outcomes (PROs).

methodsNET-PRO enrolled adults with GEP or lung NETs from 14 health systems between 2018 and 2024. SEER data included patients diagnosed with NETs from 2018 to 2021 across 22 U.S. cancer registries. We compared age, sex, race/ethnicity, tumor site, stage, and surgery between cohorts using standardized mean differences (SMDs), with values ≥ 0.2 interpreted as meaningful.

resultsWe analyzed 1,974 GEP-NET and 394 lung NET patients in NET-PRO versus 38,942 and 11,265, respectively, in SEER. Most demographic and clinical characteristics were broadly similar between cohorts, with trivial differences by sex (SMDs 0.16–0.22) and moderate differences in mean age (SMD = 0.47 for lung NETs). Race/ethnicity differences were larger, with Non-Hispanic White patients overrepresented in NET-PRO (SMDs 0.53–0.84). Tumor site and stage distributions differed modestly. Surgery rates were comparable for GEP-NETs but higher among NET-PRO lung NET patients (SMD = 0.47).

conclusionNET-PRO demonstrates broadly comparable demographic characteristics to SEER across factors such as age and sex. While race/ethnicity differences highlight areas for improved inclusion, other areas of variation suggest important future research covariates. These findings support the contextual comparability of NET-PRO with the broader NET population and its value as a resource for real-world evidence generation. NCT NUMBER: NCT05064150 (Start Date: 2022-05-10).

Indexed as

Intestinal NeoplasmsLung NeoplasmsNeuroendocrine TumorsPancreatic NeoplasmsStomach NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedPatient Reported Outcome MeasuresSEER ProgramUnited StatesCohort studiesNeuroendocrine tumorsPatient-reported outcomesReal-world evidenceSEER Program

Identifiers

PMID42043735
PMCPMC13121266

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.